The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Pre-registering a personal experiment, seriously

This is a generated summary. It shows the 9 most-liked posts from a topic of 120, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
PA
p.amankwahTL2 Moderator24 May 2025#1

Pre-registering a personal experiment, seriously — setting out what I have, and where I think it stops being reliable.

Comparing STEP 4 (JAMA, 2021) with SUSTAIN 6 (N Engl J Med, 2016) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

46 likes 14mo
JL
j.lokkenTL2 Moderator25 May 2025#5
s.stavrianos, post #4: Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people different from you. Go to post

Coming back to post #3, because the follow-up matters more than the original answer.

Sample size in n-of-1: you are the sample. Repeated measurements (weekly weighings, daily mood scores) increase the power to detect a real effect even though n=1.

33 likes in reply to #4 14mo
AK
a.kowalskiTL2 Moderator26 May 2025#16

When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.

33 likes 14mo
SO
s.okaforTL2 Moderator28 May 2025#28
dr_bhattacharya, post #25: Coming back to post #23, because the follow-up matters more than the original answer. Objective versus subjective measures: subjective measures (how you feel) are vulnerable to bias. Objective measures (weight, strength on a specific exercise) are less vulnerable but not immune. Go to post

Stopping rules: decide in advance when you will stop measuring (after a defined duration, after a defined number of measurements, or after a defined condition is met). Not deciding in advance means stopping when the result satisfies you, which is bias.

26 likes in reply to #25 14mo
SV
s.vanheckeTL2 Moderator28 May 2025#36

Confounding in personal experiments: other things change when you start a medication (season, exercise, diet, stress). Documenting those confounders helps you understand their contribution to the result.

28 likes 14mo
LV
l.vermeulenTL2 Moderator29 May 2025#48

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

29 likes 14mo
RS
r.serranoTL2 Moderator30 May 2025#56

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

31 likes 14mo
IR
i.rasmussenTL2 Moderator31 May 2025#63

Designing a personal experiment that could actually change your mind: that is the standard for an n-of-1 design. An experiment designed so that any result confirms what you already believed has not changed anything.

29 likes 14mo
KA
k.agyemanTL2 Moderator2 Jun 2025#95

When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.

32 likes 14mo

Read the full topic (120 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Designing a personal experiment that could change your mind
Posting this under the heading it deserves: Designing a personal experiment that could change your mind Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before…
MGECFACHG+2 6 695 6mo
Washout with a one-week half-life: the arithmetic — does this still hold?
Washout with a one-week half-life: the arithmetic — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021)…
AFANABANNN+41 45 12k 1d
Blinding yourself: practical methods and their limits — the long version
Blinding yourself: practical methods and their limits — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024)…
CTSDNGJEMD+7 11 1.8k 22h
An ABAB design with a data table and honest limitations
An ABAB design with a data table and honest limitations Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…
SSDSEF 2 45k 5mo
An ABAB design with a data table and honest limitations — a second dataset
On the subject in the title: An ABAB design with a data table and honest limitations — a second dataset Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…
VELIGRAC+106 118 25k 4mo

Related topics — sharing the tags worked example, data table, effect size

TopicParticipantsRepliesViewsActivity
Carryover and the ghost peak from last week's standard — what changed since
Carryover and the ghost peak from last week's standard — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the…
FDLTZYFWAA+98 114 37k 22d
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with FLOW…
VMLADNWMD+58 64 17k 13mo
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires.…
JPJAVFVBCA+99 115 11k 3mo
Preprint servers and what screening they do — the long version
On the subject in the title: Preprint servers and what screening they do — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
APNEYASSRM+7 11 26k 4mo
Coming back to: Column chemistry choices for a 40-residue peptide
On the subject in the title: Column chemistry choices for a 40-residue peptide Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise be.…
MLFPHB 2 43k 16mo